A newly approved all-oral treatment regimen is changing the way older adults with acute myeloid leukemia (AML) may receive care. Recent clinical trial findings suggest that a combination of two oral medications, Inqovi (decitabine and cedazuridine) and Venclexta (venetoclax), can deliver outcomes comparable to traditional intravenous therapies while significantly reducing the need for frequent hospital visits.
The development marks an important step forward for AML treatment, particularly for elderly patients and those who are unable to tolerate intensive chemotherapy. With both medications taken by mouth, patients may be able to receive effective leukemia treatment from home while maintaining a better quality of life.
Acute myeloid leukemia is a fast-growing cancer that begins in the bone marrow and affects the production of blood cells. The disease is more common among older adults and often presents significant treatment challenges due to age-related health conditions and reduced tolerance for aggressive therapies.
For many years, treatment options for older AML patients have relied on combinations of medications administered through injections or intravenous infusions. While these approaches can be effective, they often require repeated visits to hospitals or infusion centers, creating a substantial burden for patients and caregivers.
The newly approved oral regimen combines two medications with different mechanisms of action.
Inqovi contains decitabine, a hypomethylating agent that helps regulate abnormal cell growth associated with leukemia. The addition of cedazuridine allows decitabine to be absorbed effectively when taken orally by preventing its breakdown in the digestive system.
The medication was previously approved for treating certain blood disorders known as myelodysplastic syndromes and has now expanded its role in AML treatment.
Venetoclax targets a protein known as BCL-2, which leukemia cells often use to avoid programmed cell death. By blocking this protein, the drug helps cancer cells die naturally, improving treatment effectiveness.
Together, these medications create a fully oral treatment strategy that eliminates the need for regular intravenous administration of hypomethylating agents.
Researchers evaluated the oral combination in a multicenter clinical study involving 189 newly diagnosed AML patients from the United States, Canada, and Spain.
Participants received venetoclax continuously alongside a five-day course of decitabine-cedazuridine at the beginning of each treatment cycle.
The study produced encouraging results:
These findings suggest that the oral combination can match the effectiveness of traditional approaches while offering greater convenience.
One of the most significant advantages of this treatment is the potential reduction in hospital and clinic visits.
Traditional AML treatment protocols often require patients to receive intravenous medications for five to seven consecutive days each month. This schedule can be physically demanding, particularly for elderly individuals who may have mobility limitations or live far from treatment centers.
With the oral regimen, patients can take their medications at home under medical supervision, minimizing travel requirements and reducing disruptions to daily life.
Healthcare providers believe this convenience may help improve treatment adherence and overall patient satisfaction.
The study found that side effects associated with the oral combination were generally similar to those observed with intravenous therapies.
The most common adverse events included:
Researchers emphasized the importance of close monitoring throughout treatment. Physicians may temporarily pause venetoclax when necessary to allow healthy blood cell production to recover.
This individualized approach can help manage side effects while maintaining treatment effectiveness.
AML disproportionately affects older adults, many of whom are not candidates for intensive chemotherapy due to age or underlying health conditions.
For these patients, treatment goals often focus on balancing effectiveness with quality of life. Frequent hospital visits, prolonged infusion schedules, and treatment-related complications can significantly affect daily living.
The availability of a fully oral treatment option may help address several challenges:
These benefits may be particularly valuable for frail patients who prioritize maintaining normal routines while undergoing cancer treatment.
Although the oral regimen has shown impressive results, experts caution that it is not currently considered a cure for AML.
Patients typically need ongoing treatment to maintain remission and prevent disease recurrence. Continuous monitoring remains essential, even after achieving a favorable response.
Nevertheless, the ability to control AML effectively through oral medications represents a meaningful advancement in leukemia care.
Many specialists believe this treatment could become a preferred standard option for older adults and patients who are unable to undergo traditional chemotherapy.
Researchers are already exploring ways to improve outcomes further through the development of "triplet therapies."
These treatment strategies would add a third targeted medication to the existing two-drug combination in hopes of achieving deeper and more durable remissions.
The long-term goal is to reduce leukemia cells to extremely low levels, potentially allowing some patients to discontinue therapy altogether.
While more research is needed, the success of the current oral regimen provides a strong foundation for future innovations in AML treatment.
Patients diagnosed with AML should discuss all available treatment options with their healthcare team. Factors such as age, overall health, genetic characteristics of the leukemia, and treatment goals all play a role in determining the most appropriate therapy.
The new oral combination may be an attractive option for eligible patients seeking effective treatment with fewer hospital visits. However, regular blood monitoring and ongoing medical supervision remain critical components of care.
As treatment approaches continue to evolve, patients may benefit from increasingly personalized strategies that balance effectiveness, safety, and quality of life.
The approval of the oral combination of Inqovi and Venclexta represents an important milestone in acute myeloid leukemia treatment. Clinical trial data suggest that the regimen can provide outcomes comparable to traditional intravenous therapies while offering the convenience of at-home administration.
For older adults and patients who cannot tolerate intensive chemotherapy, this development may significantly reduce the burden of treatment without compromising effectiveness. Although not yet a cure, the therapy highlights the growing role of targeted and patient-friendly treatment approaches in modern cancer care.
As researchers continue investigating next-generation combinations, the future of AML treatment appears increasingly focused on improving both survival and quality of life.
Weill Cornell Medicine's June 2026 news release.
This article is intended for informational and educational purposes only and should not be considered medical advice, diagnosis, or treatment. Medical research findings reflect population-level results and may not apply to every individual. Patients should consult a qualified healthcare professional regarding any medical condition, treatment decision, or healthcare concern. Never disregard professional medical advice based on information found in this article.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.